[go: up one dir, main page]

RU2019113989A - Лекарственное средство - Google Patents

Лекарственное средство Download PDF

Info

Publication number
RU2019113989A
RU2019113989A RU2019113989A RU2019113989A RU2019113989A RU 2019113989 A RU2019113989 A RU 2019113989A RU 2019113989 A RU2019113989 A RU 2019113989A RU 2019113989 A RU2019113989 A RU 2019113989A RU 2019113989 A RU2019113989 A RU 2019113989A
Authority
RU
Russia
Prior art keywords
derived peptide
lag
gpc3
hsp70
protein
Prior art date
Application number
RU2019113989A
Other languages
English (en)
Other versions
RU2759728C2 (ru
RU2019113989A3 (ru
Inventor
Томоя МИЯКАВА
Сюн ДОИ
Кодзи ТАМАДА
Original Assignee
Ситлимик Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ситлимик Инк. filed Critical Ситлимик Инк.
Publication of RU2019113989A publication Critical patent/RU2019113989A/ru
Publication of RU2019113989A3 publication Critical patent/RU2019113989A3/ru
Application granted granted Critical
Publication of RU2759728C2 publication Critical patent/RU2759728C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001174—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001176—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4273—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/844—Liver
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (47)

1. Лекарственное средство, включающее:
агонист Toll-подобного рецептора и
белок LAG-3, его вариант или производное.
2. Лекарственное средство по п. 1 для комбинированного введения:
агониста Toll-подобного рецептора и
белка LAG-3, его варианта или производного.
3. Лекарственное средство по п. 1 или 2, где агонист Toll-подобного рецептора является агонистом Toll-подобного рецептора 3 или агонистом Toll-подобного рецептора 9.
4. Лекарственное средство по любому из пп. 1-3, где агонистом Toll-подобного рецептора является Поли-I:С или его соль.
5. Лекарственное средство по п. 4, где Поли-I:С является Поли-ICLC.
6. Лекарственное средство по любому из пп. 1-5, где белок LAG-3, его вариант или производное является слитым белком белка LAG-3 и IgG.
7. Лекарственное средство по любому из пп. 1-6, дополнительно включающее по меньшей мере один полученный из ракового антигена пептид.
8. Лекарственное средство по п. 7, где по меньшей мере один полученный из ракового антигена пептид является HSP70-производным пептидом или GРС3-производным пептидом.
9. Лекарственное средство по п. 7 или 8, включающее:
по меньшей мере один тип полученного из ракового антигена пептида, выбранный из группы, состоящей из НSР70-производного пептида и GРС3-производного пептида,
Поли-ICLC и
белок LAG-3 или слитый белок белка LAG-3 и IgG.
10. Лекарственное средство по п. 9, включающее HSP70-производный пептид, имеющий аминокислотную последовательность, представленную SEQ ID No: 7, или GРС3-производный пептид, имеющий аминокислотную последовательность, представленную SEQ ID No: 16.
11. Лекарственное средство по любому из пп. 7-10, включающее по меньшей мере два типа полученных из раковых антигенов пептидов.
12. Лекарственное средство по п. 11, включающее HSP70-производный пептид и полученный из ракового антигена пептид кроме НSР70-производного пептида.
13. Лекарственное средство по п. 11, включающее GPC3-производный пептид и полученный из ракового антигена пептид кроме GРС3-производного пептида.
14. Лекарственное средство по п. 11, включающее HSP70-производный пептид и GРС3-производный пептид.
15. Лекарственное средство по п. 14, включающее HSP70-производный пептид, имеющий аминокислотную последовательность, представленную SEQ ID No: 7, и GPC3-производный пептид, имеющий аминокислотную последовательность, представленную SEQ ID No: 16.
16. Лекарственное средство по п. 12, включающее:
HSP70-производный пептид, полученный из ракового антигена пептид кроме HSP70-производного пептида,
Поли-ICLC и
белок LAG-3 или слитый белок белка LAG-3 и IgG.
17. Лекарственное средство по п. 13, включающее:
GРС3-производный пептид, полученный из ракового антигена пептид кроме GРС3-производного пептида,
Поли-ICLC и
белок LAG-3 или слитый белок белка LAG-3 и IgG.
18. Лекарственное средство по п. 14, включающее:
HSP70-производный пептид, GРС3-производный пептид,
Поли-ICLC и
белок LAG-3 или слитый белок белка LAG-3 и IgG.
19. Лекарственное средство по п. 18, включающее:
HSP70-производный пептид, имеющий аминокислотную последовательность, представленную SEQ ID No: 7, и
GРС3-производный пептид, имеющий аминокислотную последовательность, представленную SEQ ID No: 16.
20. Лекарственное средство по любому из пп. 1-19 для применения в вакцинотерапии рака.
21. Лекарственное средство по любому из пп. 1-20, где лекарственное средство является противоопухолевым средством.
22. Адъювант, включающий:
агонист Toll-подобного рецептора и
белок LAG-3, его вариант или производное,
для применения в индукции специфичного иммунного ответа против раковой клетки.
23. Комбинация, включающая:
агонист Toll-подобного рецептора и
белок LAG-3, его вариант или производное,
для применения в индукции специфичного иммунного ответа против раковой клетки.
RU2019113989A 2016-10-11 2017-04-14 Лекарственное средство RU2759728C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016-200227 2016-10-11
JP2016200227 2016-10-11
PCT/JP2017/015227 WO2018070069A1 (ja) 2016-10-11 2017-04-14 医薬

Publications (3)

Publication Number Publication Date
RU2019113989A true RU2019113989A (ru) 2020-11-13
RU2019113989A3 RU2019113989A3 (ru) 2020-11-13
RU2759728C2 RU2759728C2 (ru) 2021-11-17

Family

ID=61905333

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019113989A RU2759728C2 (ru) 2016-10-11 2017-04-14 Лекарственное средство

Country Status (11)

Country Link
US (2) US11291718B2 (ru)
EP (1) EP3527216B1 (ru)
JP (1) JP6998880B2 (ru)
CN (1) CN109982711A (ru)
AU (1) AU2017342189B2 (ru)
BR (1) BR112019006075A2 (ru)
CA (1) CA3039033A1 (ru)
ES (1) ES2972560T3 (ru)
RU (1) RU2759728C2 (ru)
TW (1) TW201813664A (ru)
WO (1) WO2018070069A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3269733B1 (en) * 2015-03-09 2020-06-17 Cytlimic Inc. Peptide derived from gpc3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells
US10842848B2 (en) 2015-04-07 2020-11-24 Cytlimic Inc. Method for treating cancer by adminstering poly I:C and LAG-3-IgG fusion protein
EP3527216B1 (en) 2016-10-11 2024-02-14 NEC Corporation A medicine comprising a toll-like receptor agonist, lag-3 protein, a hsp70-derived peptide and a gpc3-derived peptide
JPWO2021106978A1 (ru) * 2019-11-27 2021-06-03
WO2025217058A1 (en) * 2024-04-08 2025-10-16 Bonum Therapeutics, Inc. Lag-3-regulatable il-2 receptor agonists

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196523A (en) 1985-01-01 1993-03-23 The University Of Southern California Control of gene expression by glucose, calcium and temperature
JPH08151396A (ja) 1994-11-28 1996-06-11 Teijin Ltd Ｈｌａ結合性オリゴペプチド及びそれを含有する免疫調節剤
RS50101B (sr) * 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju
EP0893507A1 (en) * 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
WO2000037504A2 (en) 1998-12-23 2000-06-29 Pfizer Inc. Human monoclonal antibodies to ctla-4
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
AU2002212236A1 (en) 2000-09-13 2002-03-26 Gabriele Multhoff An hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof
WO2003011895A2 (en) 2001-07-31 2003-02-13 Soederstroem Karl Petter Compositions and methods for modulation of immune responses
AU2003254950A1 (en) 2002-08-26 2004-03-11 Kirin Beer Kabushiki Kaisha Peptides and drugs containing the same
EP2572715A1 (en) 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
FR2863890B1 (fr) 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
AU2006248725A1 (en) 2005-05-19 2006-11-23 Glaxosmithkline Biologicals S.A. Vaccine composition comprising B-subunit of E. coli heat toxin and an atigen and an adjuvant
KR101304243B1 (ko) 2005-08-09 2013-09-05 온코세라피 사이언스 가부시키가이샤 ＨＬＡ-Ａ2 양성 환자용 글리피칸-3(ｇｌｙｐｉｃａｎ-3)유래의 암 거절항원 펩티드 및 그를 포함하는 의약
WO2007119515A1 (ja) 2006-03-28 2007-10-25 Dainippon Sumitomo Pharma Co., Ltd. 新規腫瘍抗原ペプチド
RU2333767C2 (ru) 2006-03-31 2008-09-20 Автономная некоммерческая организация "Институт молекулярной диагностики" (АНО "ИнМоДи") Вакцинные композиции, способы их применения для профилактики и лечения меланомы и генетические конструкции для получения действующих компонентов композиции
CN101311270A (zh) * 2006-08-18 2008-11-26 上海交通大学医学院 一种可诱生细胞免疫应答的真核表达载体及其疫苗
ES2545457T3 (es) 2006-10-17 2015-09-11 Oncotherapy Science, Inc. Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1
WO2008106491A2 (en) 2007-02-27 2008-09-04 University Of Utah Research Foundation Peptides that interact with topoisomerase i and methods thereof
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
JP2010532785A (ja) 2007-07-06 2010-10-14 ウニベルジテイト・ウトレヒト・ホールディング・ビー．ブイ． 炎症性疾患および自己免疫疾患の治療および予防
JP2010538655A (ja) 2007-09-12 2010-12-16 アナフォア インコーポレイテッド 自己免疫疾患についてのｈｓｐ７０に基づく治療
KR100900837B1 (ko) 2007-12-07 2009-06-04 (주)두비엘 리포펩타이드와 폴리(ｉ:ｃ)를 아쥬반트로 포함하는 강력한백신 조성물
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
WO2010077634A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
MY163110A (en) 2009-10-06 2017-08-15 Panacela Labs Llc Use of toll-like receptor and agonist for treating cancer
NZ599405A (en) 2009-11-24 2014-09-26 Medimmune Ltd Targeted binding agents against b7-h1
WO2012139094A2 (en) * 2011-04-08 2012-10-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of developing a vaccine using peptide-poly ic complexes
EP2785375B1 (en) 2011-11-28 2020-07-22 Merck Patent GmbH Anti-pd-l1 antibodies and uses thereof
CN104540937A (zh) * 2012-02-02 2015-04-22 新干细胞肿瘤学有限责任公司 多能胚层起源抗原呈递癌症疫苗
KR20140129124A (ko) 2012-02-07 2014-11-06 라 졸라 인스티튜트 포 앨러지 앤드 이뮤놀로지 티모시 그라스 알레르겐들 및 면역반응 조절을 위한 방법들 및 용도들
US20130217122A1 (en) 2012-02-21 2013-08-22 The Trustees Of The University Of Pennsylvania Expansion of Interferon-Gamma-Producing T-Cells Using Glypican-3 Peptide Library
WO2013143026A1 (en) 2012-03-31 2013-10-03 Abmart (Shanghai) Co., Ltd Peptide and antibody libraries and uses thereof
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
CN103961698A (zh) * 2013-02-05 2014-08-06 日东电工株式会社 经皮或粘膜给予用疫苗组合物
RU2019138702A (ru) 2013-03-01 2020-01-27 Астекс Фармасьютикалз, Инк. Комбинации лекарственных средств
US10682400B2 (en) * 2014-04-30 2020-06-16 President And Fellows Of Harvard College Combination vaccine devices and methods of killing cancer cells
JP6423889B2 (ja) 2014-10-07 2018-11-14 サイトリミック株式会社 Ｈｓｐ７０由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法
EP3269733B1 (en) 2015-03-09 2020-06-17 Cytlimic Inc. Peptide derived from gpc3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells
US10842848B2 (en) 2015-04-07 2020-11-24 Cytlimic Inc. Method for treating cancer by adminstering poly I:C and LAG-3-IgG fusion protein
WO2018021400A1 (ja) 2016-07-27 2018-02-01 国立大学法人北海道大学 がん免疫アジュバント
EP3527216B1 (en) 2016-10-11 2024-02-14 NEC Corporation A medicine comprising a toll-like receptor agonist, lag-3 protein, a hsp70-derived peptide and a gpc3-derived peptide

Also Published As

Publication number Publication date
EP3527216A1 (en) 2019-08-21
US20220175915A1 (en) 2022-06-09
EP3527216A4 (en) 2020-04-01
US11759518B2 (en) 2023-09-19
RU2759728C2 (ru) 2021-11-17
BR112019006075A2 (pt) 2019-06-18
US20200038508A1 (en) 2020-02-06
ES2972560T3 (es) 2024-06-13
AU2017342189A1 (en) 2019-05-02
US11291718B2 (en) 2022-04-05
AU2017342189B2 (en) 2023-09-21
TW201813664A (zh) 2018-04-16
EP3527216B1 (en) 2024-02-14
WO2018070069A1 (ja) 2018-04-19
JP6998880B2 (ja) 2022-02-10
RU2019113989A3 (ru) 2020-11-13
JPWO2018070069A1 (ja) 2019-09-26
CN109982711A (zh) 2019-07-05
CA3039033A1 (en) 2018-04-19

Similar Documents

Publication Publication Date Title
RU2019113989A (ru) Лекарственное средство
JP2023162283A5 (ru)
JP2015533376A5 (ru)
JP2016222689A5 (ja) 合成ペプチド及び乾燥粉末薬剤輸送システム
Liu et al. Enhanced immune response induced by a potential influenza A vaccine based on branched M2e polypeptides linked to tuftsin
RU2016122957A (ru) Способы применения интерлейкина-10 для лечения заболеваний и расстройств
JP2016519933A5 (ru)
CY1118373T1 (el) Υψηλης συγκεντρωσης υγρες μορφοποιησεις anti-tnfa αντισωματος
JP2008530245A5 (ru)
JP2011521662A5 (ru)
ES2951684T3 (es) Métodos y composiciones para estimular la respuesta inmune
JP2010500399A5 (ru)
JP2020506690A5 (ru)
JP2015529678A5 (ru)
EA202090738A1 (ru) Способ безопасного индуцирования иммунитета против rsv
JP2018510132A5 (ru)
JP2014508734A5 (ru)
JP2014502961A5 (ru)
WO2015140175A9 (en) A medicament for use in a method of inducing or extending a cellular cytotoxic immune response
RU2018116601A (ru) Иммунногенный слитый белок
Demircan et al. Biotin functionalized self‐assembled peptide nanofiber as an adjuvant for immunomodulatory response
RU2017134693A (ru) Лекарственное средство
JP2015524802A5 (ru)
US20230105457A1 (en) Immunogenic Compounds For Treatment Of Adrenal Cancer
KR101751376B1 (ko) 점막 백신